A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This randomized double-blind, placebo-controlled study will evaluate the efficacy and safety
of RO4905417 in the prevention of saphenous vein graft disease in patients undergoing
elective or urgent coronary artery bypass (CABG) surgery. Patients will be randomized to
receive either RO4905417 20 mg/kg by intravenous infusion or placebo every 4 weeks for 32
weeks.